Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | ACACA | Q13085 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25269996 | 0.86 | TSHR (0.46) | TDP1TSHRCYP2D6CYP2C19HIF1A | |
| SCHEMBL7696407 | 0.80 | HDAC3 (0.42) | TSHRCYP2D6CYP2C19HIF1AFFAR3 | |
| SCHEMBL9458196 | 0.77 | TSHR (0.39) | TDP1TSHRCYP2D6CYP2C19HIF1A | |
| SCHEMBL4057954 | 0.77 | TSHR (0.39) | TDP1TSHRCYP2D6CYP2C19HIF1A | |
| SCHEMBL9688090 | 0.77 | TDP1 (0.43) | TDP1FFAR3ALDH1A1KDM4E | |
| SCHEMBL27815841 | 0.77 | TSHR (0.39) | TDP1TSHRCYP2D6CYP2C19HIF1A | |
| SCHEMBL6450455 | 0.77 | TET2 (0.42) | TDP1TSHRCYP2D6CYP2C19HIF1A | |
| SCHEMBL1005147 | 0.76 | TSHR (0.42) | TDP1TSHRCYP2D6CYP2C19HIF1A | |
| SCHEMBL8363582 | 0.75 | EGLN1 (0.44) | TSHRCYP2D6CYP2C19HIF1AFFAR3 | |
| SCHEMBL17481554 | 0.75 | ACLY (0.42) | TDP1TSHRCYP2D6CYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4275689-A2 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-11-15 | — | — | EP | disclosed |
| EP-4275690-A2 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2023-11-15 | — | — | EP | disclosed |
| WO-2023109912-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-22 | — | — | WO | disclosed |
| US-20220002336-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2022-01-06 | — | — | US | disclosed |
| EP-3881851-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | Mitsubishi Tanabe Pharma Corporation (JP) | 2021-09-22 | — | — | EP | disclosed |
| WO-2016015160-A1 | CYCLIC UREA COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS, INC. (CA) | 2016-02-04 | — | — | WO | disclosed |
| WO-2013117137-A1 | LUPANE TRITERPENOID DERIVATIVES AND PHARMACEUTICAL USE THEREOF | JIANGXI QINGFENG PHARMACEUTICAL INC. (CN) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013020245-A1 | CARBONYL DERIVATIVES OF BETULIN | GLAXOSMITHKLINE LLC (US) | 2013-02-14 | — | — | WO | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-5081145-A | Contractile prostaglandin antagonists | MERCK FROSST CANADA, INC. (CA) | 1992-01-14 | — | — | US | disclosed |
| EP-0166591-B1 | INDOLE-2-ALKANOIC ACIDS AND THEIR USE AS PROSTAGLANDIN ANTAGONISTS | MERCK FROSST CANADA INC. (CA) | 1989-11-23 | — | — | EP | disclosed |
| EP-0166591-A2 | Indole-2-alkanoic acids and their use as prostaglandin antagonists | MERCK FROSST CANADA INC. (CA) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002336-A1 | CROSSLINKED ARTIFICIAL NUCLEIC ACID ALNA | POLN, DDX21, MUS81 | TDP1 789/4885TSHR 3132/4885CYP2D6 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.